Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
February 2018
-
Living with breast cancer in Uganda
Suzan Akello describes what life has been like since her cancer diagnosis.
-
Key ReleaseNovartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.Basel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all…
January 2018
-
Media ReleaseNovartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALLAnalysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with…
-
Media ReleaseAveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three PatientsCHICAGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening…
-
Story DiscoveryTracking patients’ progress with radio signals and machine learning
Novartis researchers leverage in-house startup initiative to begin digital technology research collaboration.
-
Featured NewsNovartis recognized as a global leader in sustainable water and climate management
Novartis is one of 73 companies included in the 2017 Water A List by CDP, the nonprofit global environmental disclosure platform.
-
Key ReleaseAdvanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine TumorsLutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced Accelerator Applications is a newly established subsidiary of Novartis Lutathera…
-
Media ReleaseNovartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision lossNovartis enters into a licensing and supply agreement to develop, register and commercialize investigational gene therapy voretigene neparvovec outside the US; Spark Therapeutics retains US rights…
-
Media ReleaseNovartis delivered good operational performance and landmark innovation in 2017, entering our next growth phaseFull year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto, more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1…
-
Media ReleaseNovartis a enregistré, en 2017, une belle performance opérationnelle et des innovations majeures, entrant ainsi dans une nouvelle phase de croissanceHausse de 2% (tcc, +1% USD) des ventes sur l'exercice complet, car l'excellente performance de nos moteurs de croissance, notamment Cosentyx et Entresto, a plus que compensé l'érosion due aux…
-
Media ReleaseNovartis erzielt 2017 eine gute operative Performance sowie wegweisende Innovationen und ist gut gerüstet für die nächste WachstumsphaseDer Umsatz steigt im Geschäftsjahr um 2% (kWk, +1% USD), wobei die starke Performance unserer Wachstumstreiber, wie Cosentyx und Entresto, die Einbussen durch Generika bei Glivec/Gleevec mehr als…
-
Featured NewsNovartis 2017 Financial Results
Pagination
- ‹ Previous page
- 1
- …
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- …
- 152
- › Next page